Blog
RSS FeedPosted by Michael Wonder on 05 Jun 2026
Teva expands European biosimilars portfolio with launch of Ahzantive (aflibercept) biosimilar to Eylea
4 June 2026 - Teva Pharmaceutical Industries today announced the launch of Ahzantive (aflibercept), a biosimilar to Eylea, in Europe further ...
Posted by Michael Wonder on 05 Jun 2026
J&J Innovative Medicine Korea wins reimbursement for Darzalex SC regimen in newly diagnosed AL amyloidosis
4 June 2026 - Johnson & Johnson Innovative Medicine Korea said Darzalex subcutaneous injection-based quadruple regimen has received reimbursement in ...
Posted by Michael Wonder on 04 Jun 2026
Why Canada has generic Ozempic, and the US doesn't
3 June 2026 - Elizabeth Doran has been taking GLP-1 medications for nearly a year for weight loss to help ...
Posted by Michael Wonder on 04 Jun 2026
AstraZeneca pulls critical breast cancer and endometriosis drug Zoladex from shelves
4 June 2026 - A life-saving breast cancer and endometriosis drug will be pulled from Australian shelves by a major ...
Posted by Michael Wonder on 03 Jun 2026
Global tensions with US President Donald Trump could threaten affordable medicines in Australia
2 June 2026 - Australia’s access to affordable medicines could be under threat from global tensions, with one woman forced to ...
Posted by Michael Wonder on 03 Jun 2026
Cheaper medicines for people fighting leukaemia and migraines
3 June 2026 - The Albanese Government is continuing to deliver cheaper medicines with Australians with types of leukaemia and ...
Posted by Michael Wonder on 02 Jun 2026
GSK secures Omjjara reimbursement in Korea, expanding access for myelofibrosis patients
1 June 2026 - GSK Korea said Monday that its myelofibrosis treatment Omjjara (momelotinib hydrochloride hydrate) has been granted reimbursement ...
Posted by Michael Wonder on 01 Jun 2026
Samsung Bioepis launches Opuviz (aflibercept) 40 mg/mL vial across Europe, to treat ophthalmic conditions
29 May 2026 - Samsung Bioepis today announced the launch of Opuviz 40 mg/mL solution for injection in a vial, ...
Posted by Michael Wonder on 01 Jun 2026
New Zealand Pharmaceutical Schedule - 1 June 2026
1 June 2026 - The June 2026 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...
Posted by Michael Wonder on 01 Jun 2026
Expanded listing to save leukaemia patients $35.5 million a year
1 June 2026 - Eligible patients with leukaemia will have access to $25 scripts for two new treatments following their ...
Posted by Michael Wonder on 29 May 2026
Foundayo and Zepbound now covered for millions of Americans
28 May 2026 - CVS Caremark begins covering Foundayo 1 June 2026 and resumes Zepbound coverage by 1 October 2026. ...
Posted by Michael Wonder on 27 May 2026
Pfizer's Braftovi becomes first Pfizer therapy to receive priority access under Ontario's FAST program, accelerating treatment for Canadians with metastatic colorectal cancer
26 May 2026 - Pfizer Canada announces that Braftovi (encorafenib) will be funded under Ontario's Funding Accelerated for Specific Treatments ...
Posted by Michael Wonder on 25 May 2026
Novo’s Sogroya gets Korea reimbursement for growth hormone deficiency
22 May 2026 - Novo Nordisk Pharma Korea said Thursday its once weekly growth hormone therapy Sogroya has received national ...
Posted by Michael Wonder on 22 May 2026
More New Zealanders could benefit from funded vaccines from 2027
21 May 2026 - PHARMAC is proposing changes that would give more New Zealanders access to funded vaccines from 2027, ...
Posted by Michael Wonder on 22 May 2026
After decade-long climb in Korea, AstraZeneca’s Tagrisso hits access wall
19 May 2026 - AstraZeneca’s Tagrisso has become strong enough in early EGFR mutated lung cancer that Korean doctors say ...